NCL-176

NCL-176 is a second-generation small molecule inhibitor of the phosphatidylinositol-3-kinase (PI3K) pathway, developed as an analog of the first-generation inhibitor DM-PIT-1. It functions as a non-lipid antagonist that disrupts the interaction between phosphatidylinositol-3,4,5-trisphosphate (PIP3) and Pleckstrin homology (PH) domains. By blocking this binding, NCL-176 prevents the recruitment and subsequent activation of PH domain-containing proteins, such as Akt, to the plasma membrane, thereby inhibiting downstream signaling essential for tumor cell growth and survival. To improve its solubility and therapeutic potential, NCL-176 has been formulated into polyethylene glycol-phosphatidylethanolamine (PEG-PE) micelles. Preclinical studies in ovarian carcinoma models (A2780) have demonstrated that NCL-176, particularly when delivered in combination with TRAIL-functionalized micelles, can significantly inhibit tumor growth and overcome TRAIL resistance.